Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to less than 89 * Mini-Mental Status Exam score of 18-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiver able to attend all clinic visits with patient * Amyloid burden on screening PET scan consistent with diagnosis of AD Exclusion Criteria: * Significant neurological disease other than AD * Major psychiatric disorder * Significant systemic illness * History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years * Smoking greater than 20 cigarettes per day * Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications * Prior treatment experimental immunotherapeutics or vaccines for AD * Women of childbearing potential * Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body